ImmVirX, a biotech startup, raised a $25M Series B to develop oncolytic viral immunotherapies. The round was led by VenturesOnes, with participation from Acorn Capital. The round valued ImmVirX at $75M. The startup's previous round was comprised of $22M led by Acorn. - ImmVirX was founded by the team that built Viralytics, which was acquired by Merck in June 2018 for $502M.
- The company began its two-part Phase 1 clinical trial of its bio-selected oncolytic virus, IVX037 to measure its activity against late-stage colorectal, gastric, and ovarian cancer.
|
